Korro Bio doses first cohort in Phase 1/2 trial for KRRO-121

Korro Bio has begun dosing the first cohort in its ANCHOR Phase 1/2 program for KRRO-121, an RNA-editing oligonucleotide for hyperammonemia. SAD/MAD studies are underway in healthy volunteers in Australia.